dx 9065a has been researched along with apixaban in 2 studies
| Studies (dx 9065a) | Trials (dx 9065a) | Recent Studies (post-2010) (dx 9065a) | Studies (apixaban) | Trials (apixaban) | Recent Studies (post-2010) (apixaban) |
|---|---|---|---|---|---|
| 92 | 7 | 8 | 2,405 | 255 | 2,250 |
| Protein | Taxonomy | dx 9065a (IC50) | apixaban (IC50) |
|---|---|---|---|
| Coagulation factor X | Homo sapiens (human) | 0.22 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Doggrell, SA | 1 |
| Arora, R; Chandrasekar, S; Loomba, R; Shah, P | 1 |
2 review(s) available for dx 9065a and apixaban
| Article | Year |
|---|---|
Is there evidence to support the use of direct Factor Xa inhibitors in coronary artery disease?
Topics: Amidines; Coronary Artery Disease; Cyclic N-Oxides; Factor Xa; Factor Xa Inhibitors; Humans; Morpholines; Naphthalenes; Propionates; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiophenes | 2011 |
The need for novel anticoagulation therapy in acute coronary syndrome.
Topics: Acute Coronary Syndrome; Administration, Oral; Anticoagulants; Cyclic N-Oxides; Factor Xa Inhibitors; Fondaparinux; Heparin; Humans; Morpholines; Naphthalenes; Polysaccharides; Propionates; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiophenes; Treatment Outcome; Warfarin | 2013 |